Please assess the completion status of the following clinical trial:

Trial Title: Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria: Healthy Volunteers~1. Male and females 21-65 years.~2. Clinically acceptable medical history~Key Exclusion Criteria: Healthy Volunteers~1. Received ionising radiation exposure from clinical trials or medical examinations or treatment in the last 12 months.~2. Suffers from claustrophobia.~3. Bilateral hip prostheses.~Key Inclusion Criteria: Patients~1. Male 18-80 years.~2. Histologically confirmed adenocarcinoma of the prostate~3. Clinically acceptable medical history~4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2~Key Exclusion Criteria: Patients~1. Biopsy 28 days prior to enrollment.~2. Extensive metastatic disease.~3. Underlying disease which might confound interpretation.~4. Bilateral hip prostheses.~5. High energy (\>300 Kiloelectron Volt (keV)) gamma-emitting radioisotope administered within five physical half-lives, or any intravenous iodinated contrast medium within 24 hours, or any high density oral contrast medium (oral water contrast is acceptable) within 5 days prior to study drug administration.~6. X-ray contrast agent (\<24 hr for intravenous agents and \<5 days for oral agents).~7. History of claustrophobia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Volunteers (Type: EXPERIMENTAL): Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
- Patients (Type: EXPERIMENTAL): Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan

Based on this trial design, predict the completion outcome and termination type (if applicable).